Paclitaxel poliglumex
Also known as: CT-2103, Paclitaxel polyglutamate, PG-TXL, Poly-L-glutamic acid paclitaxel, Xyotax
Source Paclitaxel poliglumex at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Paclitaxel poliglumex (PPX, also known as XYOTAX or CT‑2103) is an investigational polymer‑drug conjugate that links the chemotherapeutic agent paclitaxel to poly‑L‑glutamic acid. Administered intravenously, the macromolecule is designed to exploit the enhanced permeability and retention effect of tumor vasculature, delivering higher concentrations of active drug to cancer cells while limiting systemic exposure. It has been studied in non‑small cell lung cancer, ovarian cancer and other solid tumours, with early‑phase trials suggesting comparable efficacy to standard paclitaxel but with a different toxicity profile.
Mechanism of Action
PPX consists of paclitaxel covalently attached to a biodegradable poly‑L‑glutamic acid backbone. After intravenous infusion, the large conjugate preferentially accumulates in tumor tissue through the enhanced permeability and retention (EPR) phenomenon and limited lymphatic drainage. Within the tumor microenvironment, lysosomal protease cathepsin B—often up‑regulated in cancer cells—cleaves the polymer, releasing free paclitaxel. The released drug then binds to β‑tubulin, stabilizing microtubules and arresting cell division, the same intracellular mechanism as conventional paclitaxel but achieved with prolonged intratumoral exposure.
What the Research Shows
Pre‑clinical studies in animal tumour models reported that PPX provides greater antitumour activity and a wider therapeutic index than conventional paclitaxel, attributed to prolonged tumour exposure and reduced systemic levels. Phase I and II clinical investigations in advanced non‑small cell lung cancer and ovarian cancer showed encouraging response rates, a more convenient dosing schedule, and lower incidence of neutropenia, alopecia and hypersensitivity reactions, eliminating the need for routine pre‑medication. Retrospective analyses of two phase III lung‑cancer trials suggested a possible interaction with estrogen status, with improved survival trends in female patients, a hypothesis linked to estrogen‑induced cathepsin B activity. A 2021 systematic review and meta‑analysis found no significant difference in overall peripheral‑neuropathy rates between PPX and solvent‑based paclitaxel, and no overall‑survival advantage for PPX.
Reported Benefits
PPX’s polymer‑based design aims to increase tumour drug concentration while limiting systemic exposure, which early trials reported as reduced neutropenia, alopecia and hypersensitivity reactions compared with standard paclitaxel. The water‑soluble formulation removes the need for Cremophor EL solvents and associated pre‑medication. Prolonged intratumoral release may allow less frequent dosing schedules. In ovarian cancer, PPX demonstrated activity comparable to standard taxanes, and pre‑clinical data suggest enhanced efficacy when combined with radiation.
Limitations of the Evidence
Evidence for PPX remains confined to early‑phase studies and retrospective analyses; the pivotal phase III trials in non‑small cell lung cancer have not yet reported outcomes, leaving its impact on overall survival uncertain. A recent meta‑analysis showed no survival benefit and similar rates of high‑grade peripheral neuropathy versus conventional paclitaxel. Potential efficacy modulation by estrogen levels is speculative and based on limited subgroup data. Consequently, PPX is still investigational and not approved for clinical use.
Safety Considerations
Early clinical data indicate that PPX may cause fewer hypersensitivity reactions, neutropenia and alopecia than solvent‑based paclitaxel, likely due to its solvent‑free formulation and reduced systemic drug levels. However, peripheral neuropathy appears to occur at comparable frequencies, and the overall chemotherapy‑related toxicity profile remains significant. As with all taxanes, risks of myelosuppression, fatigue, and infusion‑related effects persist. Monitoring of blood counts and neurologic function is advised, and caution is warranted until definitive safety data from phase III trials become available.
How It Is Administered
PPX is administered intravenously as a sterile, water‑soluble infusion. The polymer‑drug conjugate eliminates the need for Cremophor EL solvent and routine pre‑medication for hypersensitivity. Dosing schedules explored in early trials have been less frequent than weekly solvent‑based paclitaxel, but exact regimens remain investigational.
Routes of Administration
Goals & Uses
- Ovarian cancer treatmentOncologyModerate
- Non-small cell lung cancer treatmentOncologyModerate
- Reduced hypersensitivity vs. solvent-based paclitaxelTolerability ImprovementModerate
- Improved therapeutic index via tumor targetingDrug DeliveryLow
Contraindications
- Severe hepatic impairmentOrganModerateLiver function concerns
- Severe hypersensitivity to paclitaxel or polyglutamate componentsAllergyHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Severe baseline neuropathyNeurologicalModerate
Adverse Effects
- Peripheral neuropathyNeurologicalCommon
- Hypersensitivity reactionsImmunologicUncommon
- AlopeciaDermatologicCommonHair loss
- Nausea and vomitingGastrointestinalCommon
- NeutropeniaHematologicCommonLow neutrophil count
- FatigueGeneralCommonLow energy or tiredness
Drug Interactions
- CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)Moderate
- CYP2C8 inhibitors (e.g., gemfibrozil)Moderate
- Other myelosuppressive agentsHigh
Population Constraints
- Patients with pre-existing severe peripheral neuropathyNeurologicalRelative
- Pediatric patientsAgeRelative
- Pregnant womenReproductiveAbsolute
- Severe hepatic impairmentOrgan ImpairmentRelative
Regulatory Status
- European UnionUnapprovedNo marketing authorization granted by EMA; development discontinued.
- United StatesUnapprovedNDA submitted in 2005 for first-line NSCLC; FDA issued Complete Response Letter citing lack of demonstrated superior efficacy. Not approved.
- United KingdomUnapprovedNever received MHRA approval; not commercially available.
FDA issued a Complete Response Letter in 2005 following NDA submission for first-line NSCLC treatment; approval was not granted due to insufficient evidence of superior efficacy over standard paclitaxel. The compound has not been approved by FDA, EMA, or other major regulatory agencies. Development has been largely discontinued for the original indications.
Evidence & Sources
- Journal ArticleModerateSinger JW2005-01-01T00:00:00.000000Z
- Journal ArticleModerateChipman SD, et al.2006-01-01T00:00:00.000000Z
- Journal ArticleHighTaheri A, et al.2021-01-01T00:00:00.000000Z
- Journal ArticleModerateGalic VL, et al.2011-01-01T00:00:00.000000Z
- Journal ArticleModerateSinger JW, et al.2005-01-01T00:00:00.000000Z
Frequently Asked Questions
What distinguishes paclitaxel poliglumex from conventional paclitaxel?
PPX links paclitaxel to poly‑L‑glutamic acid, creating a large, water‑soluble conjugate that preferentially accumulates in tumours via the EPR effect and releases the drug intracellularly after cleavage by cathepsin B, aiming for higher tumour exposure and lower systemic toxicity.
Has paclitaxel poliglumex been approved for any cancer indication?
No. The compound remains investigational; it has been studied in phase I‑III clinical trials for non‑small cell lung cancer and ovarian cancer, but regulatory approval has not been granted.
Does PPX reduce the common side effects of paclitaxel, such as hypersensitivity and neutropenia?
Early phase studies reported lower rates of hypersensitivity reactions, neutropenia, and alopecia compared with solvent‑based paclitaxel, likely because PPX is solvent‑free. However, peripheral neuropathy rates appear similar, and overall safety data are still limited.
How is paclitaxel poliglumex given to patients?
It is delivered as an intravenous infusion of a sterile, water‑soluble solution. The formulation does not require Cremophor EL, and routine pre‑medication for hypersensitivity has not been needed in early trials, though dosing schedules are still under investigation.
What is Paclitaxel poliglumex?
Paclitaxel poliglumex (PPX, also known as XYOTAX or CT‑2103) is an investigational polymer‑drug conjugate that links the chemotherapeutic agent paclitaxel to poly‑L‑glutamic acid. Administered intravenously, the macromolecule is designed to exploit the enhanced permeability and retention effect of tumor vasculature, delivering higher concentrations of active drug to cancer cells while limiting systemic exposure. It has been studied in non‑small cell lung cancer, ovarian cancer and other solid tumours, with early‑phase trials suggesting comparable efficacy to standard paclitaxel but with a different toxicity profile.
What is Paclitaxel poliglumex used for?
Paclitaxel poliglumex is educationally associated with: Ovarian cancer treatment, Non-small cell lung cancer treatment, Reduced hypersensitivity vs. solvent-based paclitaxel, Improved therapeutic index via tumor targeting. Educational only — not medical advice.
How is Paclitaxel poliglumex administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Paclitaxel poliglumex?
Reported adverse effects include: Peripheral neuropathy, Hypersensitivity reactions, Alopecia, Nausea and vomiting, Neutropenia, Fatigue. This list is not exhaustive — consult a qualified clinician.
Who should avoid Paclitaxel poliglumex?
Recorded contraindications: Severe hepatic impairment, Severe hypersensitivity to paclitaxel or polyglutamate components, Pregnancy, Severe baseline neuropathy. Consult a qualified clinician before use.